imbruvica
Ibrutinib Bests Drug Combo in Older CLL Pts
San Diego—In older patients with newly diagnosed chronic lymphocytic leukemia (CLL), the BTK inhibitor ...
MARCH 4, 2019
Imbruvica Approved to Treat Waldenström Macroglobulinemia With Rituxan
The FDA approved the use of ibrutinib (Imbruvica, Pharmacyclics/Janssen) in combination with rituximab ...
AUGUST 30, 2018
FDA Approves Imbruvica to Treat Adults With Chronic GVHD
Imbruvica becomes the first and only therapy specifically approved for adults with cGVHD, a serious and ...
AUGUST 8, 2017
Anti-CD20 Therapy Boosts Efficacy of Ibrutinib in CLL
Chicago—When added to the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or ...
JULY 20, 2017
Immunotherapies for CLL Complement Targeted Agents
In CLL, the activity of immunotherapies may be enhanced when they are administered in combination with ibrutinib ...
MARCH 23, 2017
Imbruvica Approved for First-Line Treatment of CLL
The therapy is approved as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).
MARCH 8, 2016
